New antibody shows strong potential against pancreatic cancer

Press Releases, Uncategorized
SIWA318H specifically targets and removes senescent cells in pancreatic tumors, slowing their growth PHOENIX, AZ — Oct. 12, 2023  — Scientists at the Translational Genomics Research Institute (TGen), part of City of Hope, in collaboration with SIWA Therapeutics Inc., recently published results from a preclinical study that highlights the potential of SIWA318H, an advanced glycation end product (AGE)-targeting antibody, in the fight against pancreatic cancer. The results appear in Scientific Reports, a Nature publication. Pancreatic cancer, especially pancreatic ductal adenocarcinoma (PDAC), has long been known for its aggressive nature and resistance to current treatment options. SIWA318H’s ability to selectively target senescent cells represents a new approach to treating the disease. Senescent cells within the tumor microenvironment have been identified as major contributors to tumor development, growth and therapy resistance. SIWA318H, an antibody specifically designed to target AGEs, offers…
Read More

SIWA Therapeutics, Inc. Presents New Data at the November 2022 American Association for Cancer Research Aging and Cancer Conference

Uncategorized
You can view the poster by clicking here.Chicago, IL., November 21, 2022, The aging-related and cancer cell-derived oxidatively-stressed tumor microenvironment and other cell damages drive cell senescence and other oxidative cellular responses. Tumor fibrosis reduces the effectiveness of anti-cancer immune responses and senescent cells (SCs), in turn, promote immune suppression, tumor progression, and metastasis. Hence, according to a study conducted by Translational Genomics Research Institute on behalf of SIWA Therapeutics, Inc. as presented by Dr. Gabriela Rossi, Chief Research Officer of SIWA Therapeutics, Inc. (“SIWA”) at the AACR Special Conference: Aging and Cancer November 17 -20, 2022, targeting damaged cells, including SCs and cancer cells, with SIWA318H, presents an attractive approach for cancer therapy. SIWA318H is a monoclonal antibody that selectively targets an advanced glycation end product oxidative stress biomarker…
Read More

SIWA Therapeutics Announces Promising Results in New Pancreatic Cancer Study

Uncategorized
CHICAGO, March 14, 2022 -- PRNewswire -- SIWA Therapeutics, Inc. (“SIWA”), a Chicago-based biopharmaceutical company announced today that SIWA’s proprietary humanized monoclonal antibody, SIWA318H, is efficacious in an immune competent humanized mouse xenograft model for pancreatic cancer. The study was conducted by the Translational Genomics research Institute (“TGEN”), pursuant to a SIWA-sponsored research agreement. Results of the pancreatic cancer study in humanized mice treated with SIWA318H included: Both the SIWA318H high dose and low dose treatment groups showed significant anti-tumor activity in a PSN1 human pancreatic cancer mouse xenograft tumor model by significantly reducing tumor growth (P-Value < 0.0001); There was a significantly higher number of complete remission cases in the treated groups compared to the isotype-treated control group. 37.5% (6 out of 16 mice) treated with SIWA318H high dose had…
Read More

SIWA Therapeutics, Inc. Appoints Deborah Wince-Smith to Board of Directors

Uncategorized
CHICAGO, Feb. 24, 2022 /PRNewswire/ -- SIWA THERAPEUTICS, INC, which has developed SIWA318H, a proprietary monoclonal antibody that has caused complete remission of pancreatic cancer in vivo in humanized mice, announced today that it has appointed Deborah Wince-Smith to its Board of Directors, effective February 22, 2022.Ms. Wince-Smith is the President and CEO of the Council on Competitiveness, a coalition of CEOs, university presidents, labor leaders and national laboratory directors, committed to driving U.S. competitiveness. She has more than 20 years of experience as a senior U.S. government official, as the first Senate-confirmed Assistant Secretary for Technology Policy in the U.S. Department of Commerce in the Administration of President George H.W. Bush, and as the Assistant Director for International Affairs in the White House Office of Science and Technology Policy in the Reagan Administration. She served as…
Read More